Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study Abstract #2083

Introduction: Predicting treatment response at an early stage in the treatment algorithm for NET is highly desirable.
Aim(s): To investigate 92 putative cancer-related proteins in plasma at the time of diagnosis and after 6 months of treatment in an attempt to explore new predictive biomarkers.
Materials and methods: One hundred small intestinal NET patients from 16 Nordic centers were prospectively followed. Blood samples were obtained before start of treatment, and 6 (±3) months after initiation of treatment. Plasma samples were analysed with Olink Proseek Multiplex Oncology II panel. Chromogranin A (CgA) was analysed centrally at Akademiska Lab Uppsala (NEOLISA Euro Diagnostica). Treatment response was analysed using a logistic regression model adjusted for the baseline CgA value and the baseline value of the biomarker.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Associate prof, Magnus Kjellman

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1694 Plasma Protein Fingerprinting for the Diagnosis of Small Intestinal Neuroendocrine Tumors (siNETs)
Introduction: siNETs are notoriously difficult to diagnose, especially in an early stage.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: MD PhD Magnus Kjellman
#672 Affinity Proteomic Plasma Analysis of Human Well-Differentiated Small Intestinal Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumor (SI-NET) patients get diagnosis at the stage of metastasis and there is a lack of curative treatments.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Assoc. Prof, PhD Valeria Giandomenico
Authors: Darmanis S, Cui T, Li S C, Öberg K, ...
#152 Validation of a new assay that uses 2 monoclonal antibodies to measure intact and fragmented plasma CgA levels
Introduction: Plasma chromogranin A (CgA) levels are elevated in a variety of neuroendocrine tumors (NETs) and are used to aid in diagnosis, prognosis, and monitoring of treatment effects in NETs patients. We evaluated a newer sandwich ELISA assay (Cisbio US, Bedford, MA, USA) that utilizes two monoclonal antibodies that bind to the mid-region of the CgA protein and allow measurement of intact and fragmented circulating CgA. The results from the assay validation indicative of its overall robustness in terms of sensitivity, specificity, reproducibility, and stability are presented here.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Monica Motwani
#12 Chromogranin A as a predictor of progression, regression or stable disease in ileo-cecal (midgut) carcinoid tumors
Introduction: A general characteristic for NETs is their expression of certain proteins, such as chromogranin A (CgA), which is released from the dense core vesicles of NE cells, occasionally together with cell specific hormones, such as gastrin and serotonin. Plasma CgA seems to be closely related to tumor burden of intestinal carcinoid tumors in humans.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kenneth Jensen
#1455 Expression of Mutated p53 Protein in Gastroenteropancreatic Neuroendocrine Carcinoma (WHO G3)
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, highly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short-lasting.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: PhD student Abeir Ali